Antibody-directed enzyme prodrug therapy (ADEPT).

Area of Science:

• Oncology
• Biochemistry
• Immunology

Background:

• Targeted cancer therapy aims to deliver cytotoxic agents specifically to tumor cells.
• Antibody-drug conjugates (ADCs) are a promising approach, but their efficacy can be limited by penetration into the tumor microenvironment.
• The bystander effect, where a released drug affects neighboring cells, could enhance ADC efficacy.

Purpose of the Study:

• To evaluate the targeting and cytotoxic potential of a carboxypeptidase G2-A5B7 antibody conjugate.
• To investigate the bystander effect of a phenol mustard prodrug released by the conjugate.
• To assess the conjugate's efficacy against human colon (LS174T) and lung (COR-L23) tumor cell lines.

Main Methods:

• In vitro studies using human colon tumor cell line LS174T and lung cell line COR-L23.
• Indirect immunofluorescence microscopy to assess conjugate binding.
• Cytotoxicity assays to determine IC50 values after prodrug activation.

Main Results:

• The carboxypeptidase G2-A5B7 conjugate selectively bound to LS174T colon cancer cells, not COR-L23 lung cells.
• Significantly greater cytotoxicity was observed in LS174T cells (IC50=0.24 μM) compared to COR-L23 cells (IC50=108 μM) after prodrug addition.
• In a mixed cell population, a bystander effect was evident, with an IC50 of 3.4 μM, indicating localized drug release impacted neighboring cells.

Conclusions:

• The antibody-enzyme conjugate demonstrates specific targeting of colon cancer cells.
• Localized release of phenol mustard via the conjugate induces a bystander effect, enhancing tumor cell killing.
• This approach holds potential for improving localized cancer therapy by affecting non-targeted neighboring cells.